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Abstract
Background: Telehealth interventions use information and communication technology to provide clinical support.
Some randomised controlled trials of telehealth report high patient decline rates. A large study was undertaken to
determine which patients decline to participate in telehealth trials and their reasons for doing so.
Methods: Two linked randomised controlled trials were undertaken, one for patients with depression and one for
patients with raised cardiovascular disease risk (the Healthlines Study). The trials compared usual care with
additional support delivered by the telephone and internet. Patients were recruited via their general practice and
could return a form about why they were not participating.
Results: Of the patients invited, 82.9 % (20,021/24,152) did not accept the study invite, either by returning a decline
form (n = 7134) or by not responding (n = 12,887). In both trials patients registered at deprived general practices
were less likely to accept the study invite. Decline forms were received from 29.5 % (7134/24,152) of patients invited.
There were four frequently reported types of reasons for declining. The most common was telehealth-related: 54.7 %
(3889/,7115) of decliners said they did not have access or the skills to use the internet and/or computers. This was
more prevalent amongst older patients and patients registered at deprived general practices. The second was health
need-related: 40.1 % (n = 2852) of decliners reported that they did not need additional support for their health
condition. The third was related to life circumstances: 27.2 % (n = 1932) of decliners reported being too busy.
The fourth was research-related: 15.3 % (n = 1092) of decliners were not interested in the research.
Conclusions: A large proportion of patients declining participation in these telehealth trials did so because they
were unable to engage with telehealth or did not perceive a need for it. This has implications for engagement with
telehealth in routine practice, as well as for trials, with a need to offer technological support to increase patients’
engagement with telehealth. More generally, triallists should assess why people decline to participate in their studies.
Trial registration: The Healthlines Study has the following trial registrations: depression trial: ISRCTN14172341
(registered 26 June 2012) and CVD risk trial: ISRCTN27508731 (registered 05 July 2012).
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Background
“Telehealth is the remote exchange of data between a pa-
tient at home and their clinician(s) to assist in diagnosis
and monitoring typically used to support patients with
Long Term Conditions” [1]. Examples of telehealth in-
clude online cognitive behavioural therapy, home moni-
toring of health parameters such as blood pressure and
internet-based health forums. Globally, telehealth is
becoming a prominent part of healthcare delivery.
Telehealth interventions are increasingly being tested in
randomised controlled trials (RCTs). Some of these tele-
health trials have reported high decline rates of over
75 % amongst potential participants [2, 3]. A recent re-
view of 37 telehealth studies found an average decline
rate of 32 %, but this varied between 4 % and 71 % for
the individual studies; and only two studies were RCTs
[4]. Decline rates may vary because of the health condi-
tion under study. For example, some patient groups are
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known to be especially difficult to recruit, such as those
with depression [5]. An alternative explanation is that
selection criteria may have differed between trials. It is
also possible that the nature of the telehealth interventions
being tested affected the decline rates due to varying levels
of acceptability amongst potential participants.
High decline rates in RCTs generally are problematic
because they may result in underpowered trials or
extended recruitment periods which have resource
implications [6]. Additionally, if those declining are not
representative of the clinical population, external validity
may be compromised [7]. High decline rates may also
indicate problems with the acceptability of the interven-
tion, with implications for its uptake when delivered in
routine practice. This latter issue may be particularly
relevant to telehealth trials, since there may be physical
barriers in terms of accessing technology [8], as well as
psychological barriers such as low confidence in using
the technology [9]. Understanding which types of
patients do not participate in telehealth trials, and why,
may help to improve recruitment rates, external validity
and interpretation of trial results.
There has been some research examining the types of
patients who do not participate in telehealth trials. No
gender differences have been found in telehealth trials
[2] or telehealth studies which use other methodologies
[4]. Older adults are more likely not to participate in tel-
ehealth trials [2, 10] due to technological demands and
because they have less access to technology [8, 9, 11].
This higher non-participation rate amongst older people
also mirrors RCTs more generally [12, 13]. In terms of
differences in participation amongst socio-economic
groups, one telehealth trial did not find any differences
[2]. However, studies of routine telehealth services
report lower uptake amongst patients from lower socio-
economic groups [14]. This mirrors the evidence based
more generally on healthcare research, where there are
lower response rates from patients experiencing greater
socio-economic deprivation [15, 16]. There is no
evidence on participation in telehealth trials by ethnic
minority groups. However, these groups are usually
under-represented in RCTs in the United Kingdom and
North America, partly because a common exclusion
criterion is the inability to speak English fluently [17].
To date, only a handful of studies have explored why pa-
tients do not participate in telehealth studies [2, 3, 8, 18].
These have been fairly small quantitative studies of 625,
331 and 79 patients [18, 2, 3], with only one qualitative
study with 19 patients [8]. There was a review of why pa-
tients may not participate in telehealth research, but this
was in relation to telehealth studies in general, rather than
RCTs specifically [4]. Eight main reasons for declining
participation in telehealth trials have been identified. First,
patients have concerns, and in some cases anxiety,
regarding the technological aspects of the intervention
[2, 8, 18]. Second, some patients do not perceive the inter-
vention to be beneficial [3, 18]. Third, some patients
prefer face-to-face care, rather than healthcare delivered
remotely, which is an integral component of telehealth in-
terventions [2]. Fourth, some patients believe that there is
no need for the intervention, for example, because routine
healthcare is sufficient [3]. Fifth, many patients decline
due to poor health [2, 19] or perceive their older age to be
a barrier [2]. Sixth, patients are simply not interested [4],
but it is not clear whether patients are not interested in
the telehealth intervention or the research itself. Seventh,
patients simply do not want to participate in the study [18].
Finally, some patients are too busy to participate [18].
These mirror some of the reasons why patients decline to
participate in RCTs more generally: patients are not inter-
ested or are too busy, are too ill, perceive themselves as
ineligible, have transport barriers, have concerns about the
intervention or do not want to be randomised [20–22].
Given the high decline rate in some telehealth trials
and the limited literature investigating this topic, it is
important to understand more about which patients do
not choose to participate in telehealth trials and their
reasons for this choice. We utilised recruitment data for
two large linked RCTs of telehealth (the Healthlines
Study) to undertake a quantitative study of who does
not participate in telehealth trials and why.
Methods
The Healthlines Study
The Healthlines Study consists of two linked RCTs of a
telehealth intervention, one for patients with depression
and one for patients with a raised risk of cardiovascular dis-
ease (CVD risk) [23]. The telehealth intervention consisted
of up to 12 months of telephone support from a health in-
formation advisor and access to a range of online resources,
including computerised cognitive behavioural therapy soft-
ware packages, support for home monitoring (such as
blood pressure monitoring) and links to online educational
and support tools. To participate in the trials, patients had
to have at least weekly access to an email account and the
internet. The trials were approved by the National Research
Ethics Service Committee South West-Frenchay (Reference
12/SW/0009) and have the following trial registrations:
depression trial: ISRCTN14172341 (registered 26 June
2012) and CVD risk trial: ISRCTN27508731(registered 05
July 2012).
Recruitment of patients
Patients were recruited via 43 general practices between
June 2012 and July 2013. Searches of practice records
were undertaken to identify potential participants. For
the depression trial, patients were identified who were
aged 18 to 100 years old, and in the preceding three
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months to the search visit were coded as having depres-
sion, anxiety or low mood, or who were issued an anti-
depressant prescription. Exclusion criteria were applied
such as having psychosis, substance abuse issues or de-
mentia. For the CVD risk trial, patients were selected
who were aged 40 to 74 years and, based on data in rou-
tine general practice records, were estimated to have at
least a 19 % risk of having a cardiovascular event in the
next ten years and had one or more modifiable risk fac-
tors (being a smoker, overweight or having high blood
pressure). Exclusion criteria were applied including
being identified as part of the depression trial or having
had a cardiovascular event, such as a heart attack or
stroke. General practitioners at each practice were asked
to exclude any patients they felt were unsuitable, for
example, the recently bereaved [23]. After exclusions,
16,570 patients were invited to participate in the depres-
sion trial, and 7582 patients in the CVD risk trial. A
larger number of patients were invited in the depression
trial because it was anticipated that there would be a
lower participation rate.
Practice staff sent the selected patients an information
pack, including a personalised invitation letter, a patient
information booklet, an acceptance form, a decline form
and a freepost envelope. Approximately three weeks later,
patients who had not responded were re-sent the informa-
tion packs.
Acceptors, active decliners and non-responders
Invited patients could return an acceptance form (accep-
tors). On receipt of this form, they were contacted by a
researcher to assess their eligibility. Alternatively,
patients could return a decline form (active decliners),
or choose not to respond (non-responders). The decline
form was anonymous, but linked to demographic infor-
mation from the general practices through a study ID
number. Patients were asked to indicate why they were
declining to participate by ticking one or more of the
pre-specified reasons provided on the form, including:
 I do not have regular access to the internet or an
email address
 I do not feel confident enough with computers
 I am too busy at the moment
 I do not feel I need any more support with my
health at this time
 I am not interested in this research
The pre-specified reasons incorporated the common
reasons for declining reported in previous literature on
uptake in telehealth studies and RCTs more generally. In
addition, there was an ‘other reason’ that responders
could select, and they were asked to specify this reason
in a free text box. A small proportion of patients (4.2 %,
n = 1020/24,152) were sent a decline form with the
additional pre-specified reason of ‘I do not understand
the study’. This was part of a sub-study where patients
were sent a re-designed written patient information
sheet to explore whether this increased recruitment [23].
Data on the age, sex and ethnicity of invited patients
was collected from the general practice records. However,
ethnicity was poorly recorded in practice records, and the
study had to reply on self-report from patients who
returned forms. For this reason, ethnicity is missing for
non-responders. Levels of socio-economic deprivation
were derived from the general practice at which patients
were registered.
Analysis
A two-stage analysis was conducted. The first stage was
a comparison of the socio-demographic characteristics
of the different response types. This included comparing
the acceptors with a combined category of active
decliners and non-responders. A comparison of active
decliners and non-responders was then conducted to
understand the effect of non-response bias on our study
of why patients declined. Data were entered into SPSS.
Ethnicity was re-categorised from multiple ethnicity cat-
egories into a dichotomous variable of White or Black
and Minority Ethnicity (BME). A variable was created to
capture socio-economic deprivation based on the
general practice at which a patient was registered.
Deprivation was defined by the decile attributed to a
general practice in the National Practice Profiles [24].
Patients registered at practices in deciles 1–5 were coded
as ‘deprived’ and patients registered at practices in
deciles 6–10 were coded as ‘affluent’. Chi-square and in-
dependent t-tests were undertaken to test for differences
by age, gender, ethnicity and deprivation.
The second stage involved exploring the reasons why
patients declined to participate in the trials. Frequencies
and percentages were calculated to understand the
prevalence of each reason. The other reasons patients
provided for declining were coded by one researcher
(AF) and checked by another researcher (KAH). Of the
979 patient-reported ‘other’ comments in the depression
trial, the researchers initially disagreed on the coding for
204 (20.8 %). Of the 551 CVD risk ‘other’ comments,
there was disagreement on 63 (11.4 %). These comments
were discussed and consensus reached on coding.
As a considerable proportion of responders declined
because of technology-related reasons, and this issue is
intrinsic to telehealth, further analysis was conducted.
Responders were categorised as declining for a technology-
related reason if they had selected the pre-specified reasons
of no internet access or no computer confidence, or if
they provided their own reason related to technology
issues, such as not having a computer. Technology-related
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decliners were compared with other types of decliners by
age, gender, ethnicity and deprivation. Chi-square and
independent t-tests were undertaken.
Results
Responses to the Healthlines Study invitation
Overall, 82.9 % (20,021/24,152) of the patients invited
did not accept the study invite (Table 1). Most of these
patients (n = 12,887) did not respond at all, but decline
forms were received from 29.5 % (n = 7134) of all pa-
tients invited (Table 1). Response type differed by health
condition, with patients with depression more likely not
to accept than those with raised CVD risk (84 % depres-
sion versus 80 % CVD risk, P ≤ 0.001, X2 = 452.8, df = 1).
Socio-demographic characteristics
Decliners (active decliners and non-responders) compared
to acceptors
All those that declined the invite (active decliners and
non-responders) were compared with those accepting
the invite (Tables 2 and 3). In the depression trial, males
(86 %, n = 4570) were more likely to decline than females
(84 %, n = 9419), P ≤ 0.001, X2 = 11.43, df = 1. In the
CVD risk trial, females (83 %, n = 1675) were more likely
to decline than males (78 %, n = 4357 males), P ≤ 0.001,
X2 = 18.26, df = 1. Although the differences were statisti-
cally significant, they were not large for the depression
trial. Of those whose ethnicity was known, in the depres-
sion trial there was no difference in decline rates be-
tween white patients (87 %, n = 4152) and BME patients
92 %, n = 82), P = 0.168, X2 = 1.90, df = 1), although num-
bers were small. In contrast, there was some evidence in
the CVD risk trial that patients from BME groups (82 %,
n = 78) were more likely to decline than white patients
(70 %, n = 2553), P = 0.08, X2 = 6.94, df = 1). Patients
from deprived general practices were more likely to
decline compared with patients from affluent general
practices in both the depression and CVD risk trials
(Depression: 87 %, n = 3947 deprived versus 84 %,
n = 10,042 affluent declined, P ≤ 0.001, X2 = 21.4, df = 1;
CVD risk: 85 %, n = 1725 deprived versus 78 %, n = 4307
affluent declined, P ≤ 0.001, X2 = 42.93, df = 1). In the de-
pression trial, there was no difference in the mean age of
decliners compared to acceptors (Mean age: Decliners:
50.66 years old versus Acceptors: 50.79, P = 0.710,
t = −0.371). In the CVD risk trial, however, there was a
statistically significant difference, with decliners being
younger than acceptors (Mean age: Decliners: 65.75 years
versus Acceptors: 66.33 years, P = 0.001, t = −3.321),
although the mean difference in age was less than a year.
Active decliners compared to non-responders
Of the patients who did not accept the study invite, de-
cline forms were received from 35.6 % (7134/20,021).
The active decliners were compared to non-responders
to understand how representative active decliners were
of all patients who did not accept the study invite. In
both the depression and CVD risk trials, females were
more likely to return decline forms compared to males
(Depression: 41 %, n = 3049 females versus 29 %, n =
1333 males, P ≤ 0.001, X2 = 14.67, df = 1; CVD risk: 54 %,
n = 907 females versus 42 %, n = 1845 males, P ≤ 0.001,
X2 = 67.95, df = 1). Ethnicity could not be compared be-
cause the data were not available for non-responders. In
both trials, patients registered at affluent practices were
more likely to return decline forms compared to patients
registered at deprived practices (Depression: 32 %, n =
3239 affluent versus 29 %, n = 1143 deprived, P ≤ 0.001,
X2 = 14.31, df = 1; CVD risk: 46 %, n = 2001 affluent ver-
sus 43 %, n = 751 deprived, P = 0.039, X2 = 4.24, df = 1),
although differences were not large. In both trials, pa-
tients who returned decline forms were more likely to
be older than non-responders (Depression: Mean age:
Active decliners: 59.7 years versus Non-responders:
46.5 years, P ≤ 0.001, t = −45.679; CVD risk: Mean age:
Active decliners: 67.4 years versus Non-responders:
64.4 years, P ≤ 0.001, t = −18.740).
Reasons for declining
Number of reasons for declining
Of the 7134 decline forms received, 19 were blank. These
have been included in the response type calculations
above, but they have been excluded from the reasons for
decline analysis below. Ninety-nine percent (n = 7045) of
patients who returned a decline form provided a reason
for declining to participate in the trial (Depression: 98.9 %,
n = 4327; CVD risk: 99.1 %, n = 2718). Most decliners pro-
vided only one (Depression: 47.2 %, n = 2062; CVD risk:
39.4 %, n = 1079) or two reasons (Depression: 29.4 %,
n = 1287; CVD risk: 33.6 %, n = 922).
In both health conditions, over 90 % of decliners
selected at least one of the pre-specified reasons on the
form (Depression: 90.4 %, n = 3954; CVD risk: 93.8 %,
n = 2571). Some patients provided another reason, with
more patients in the depression trial doing this compared
to the CVD risk trial (Depression: 23.5 %, n = 1021; CVD
risk: 16.1 %, n = 441). In both health conditions, a small
number of responders specified a reason that was compat-
ible with one of the pre-specified reasons (Depression: 62;
Table 1 Frequency of response type by health condition
Type of response
Accepted Declined Non-responders Total
N % N % N % N %
Depression RCT 2581 (15.6) 4382 (26.4) 9607 (58.0) 16,570 (100)
CVD RCT 1550 (20.4) 2752 (36.3) 3280 (43.3) 7582 (100)
Total 4131 (17.1) 7134 (29.5) 12,887 (53.4) 24,152 (100)
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CVD risk: 29). These were added to the frequencies of the
pre-specified reasons. A small number of responders
ticked the other reason option, but instead of specifying a
reason, they wrote a comment, such as “thank you, but no
thank you” (Depression: 17; CVD risk: 8); these are not
included below.
People mainly ticked the pre-specified categories
(Table 4), with one in five giving other reasons for de-
clining (Table 5). Both the pre-specified reasons and the
other reasons were categorised into four domains. These
domains were developed thematically based on concep-
tual similarities.
Telehealth-related reasons
Telehealth-related reasons, in terms of no computer confi-
dence and/or no internet access, were prominent pre-
specified reasons (Table 4), affecting 54.7 %, n = 3889 of
active decliners. A small number of active decliners also
specified that they were not participating because they did
not like the telehealth intervention (1.4 %, n = 102), pri-
marily because it was being delivered remotely rather than
face-to-face; because of communication difficulties, such
as a visual impairment, which meant that engagement in a
telehealth intervention was problematic (1.3 %, n = 92);
and because of practical barriers, such as not having a
computer (1.3 %, n = 94).
Health need
A lack of perceived health need was the second most
frequent option in the pre-specified reasons (40.1 %, n =
2852). A small number of people also declined because
they were satisfied with their current level of support,
such as having regular health checks (3.1 %, n = 222), or
they were currently receiving treatment for other health
conditions (3.4 %, n = 245).
Patients’ lives
The fourth most common reason for declining was be-
ing too busy (27.2 %, n = 1932). Some decliners provided
other related reasons such as not having space in their
life to participate in a trial, which sometimes related to
not having the emotional capacity to participate (3.4 %,
n = 243); or indicating that it was an inconvenient time
to join the study, for example, because of planned time
away from home (2.7 %, n = 189).
Research-related reasons
A lack of interest in the research was given as the fifth
most common reason for declining (15.3 %, n = 1092).
Related reasons were that patients perceived themselves
as unsuitable for the trial, for example, because they did
not have depression (1.9 %, n = 134); or the trial could
be distressing, such as having to discuss health issues
Table 2 The characteristics of the different response types for the depression trial
Accepted
n (%)
Declined
n (%)
Non-responders
n (%)
All
N =100 %
Gender Female 1825 (16.2) 3049 (27.1) 6370 (56.7) 11,244
Male 756 (14.2) 1333 (25.0) 3237 (60.8) 5326
Ethnicity White 609 (12.8) 4152 (87.2) N/A 4761
BME 7 (7.9) 82 (92.1) 89
Deprivation Affluent 1967 (16.4) 3239 (27.0) 6803 (56.6) 12,009
Deprived 614 (13.5) 1143 (25.1) 2804 (61.5) 4561
Age (mean, (SD)) 50.8 (13.87) 59.7 (15.94) 46.5 (15.85) 50.7
Total 2581 (15.6) 4382 (26.4) 9607 (58.0) N = 16,570
Table 3 The characteristics of the different response types for the CVD risk trial
Accepted
n (%)
Declined
n (%)
Non-responders
n (%)
All
N =100 %
Gender Female 347 (17.2) 907 (44.9) 768 (38.0) 2022
Male 1203 (21.6) 1845 (33.2) 2512 (45.2) 5560
Ethnicitya White 1118 (30.5) 2553 (69.5) N/A 3671
BME 17 (17.9) 78 (82.1) N/A 95
Deprivation Affluent 1235 (22.3) 2001 (36.1) 2306 (41.6) 5542
Deprived 315 (15.4) 751 (36.8) 974 (47.7) 2040
Age (mean, (SD)) 66.3 (5.59) 67.4 (5.24) 64.4 (6.2) 65.87
Total 1550 (20.4) 2752 (36.3) 3280 (43.3) N = 7582
aData on ethnicity was not available for non-responders
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(1.9 %, n = 132). Both these reasons were more prevalent
in the depression than in the CVD risk trial. A small
number of patients (1.6 %, n = 111) specified other rea-
sons related to the research, including confidentiality
concerns and perceiving the research as a waste of
money or resources.
Technology-related reasons
Further analysis was conducted to compare responders
who actively declined for technology-related reasons to
those who actively declined for non-technology issues
(Table 6). Decliners in the CVD risk trial were more
likely to offer a technology-related reason than those in
the depression trial (P ≤ 0.001, X2 = 126.93, df = 1). In the
CVD risk trial, 63 % (n = 1729) of patients gave at least
one reason for declining that was related to technology
issues compared with 49 % (n = 2160) in the depression
trial. There were some differences in the demographics
of patients who declined for technology reasons com-
pared with non-technology reasons. In the CVD risk
trial, females were more likely to decline for a technol-
ogy reason than males (P = 0.011, X2 = 6.52, df = 1), al-
though there was no such difference in the depression
trial (P = 0.508, X2 = 0.44, df = 1). Across both trials,
there was no statistically significant difference in the
ethnicity of patients who declined because of technology
issues and those that did not (Depression: P = 0.590, X2
= 0.29, df = 1; CVD risk: P = 0.281, X2 = 1.16, df = 1), al-
though the direction was that technology issues affected
more people from BME communities. In both trials, pa-
tients were more likely to decline because of technology
reasons if they were registered at deprived practices
(Depression: P ≤ 0.001, X2 = 30.98, df = 1; CVD risk:
P ≤ 0.001, X2 = 21.22, df = 1), or older (Depression:
P ≤ 0.001, t = −35.683; CVD risk: P = 0.001, t = −3.352).
This age difference was more pronounced in the depres-
sion trial, where there was a mean age difference of
15 years between patients who declined for technology
reasons and those who declined for non-technology rea-
sons compared with a one-year difference for CVD risk.
Table 4 Pre-specified reasons for declining
Reason Depression
n (%)
CVD risk
n (%)
Both conditions
n (%)
No internet access 1834 (41.9) 1491 (54.4) 3325 (46.7)
No need for additional support with health issues 1717 (39.3) 1135 (41.4) 2852 (40.1)
No computer confidence 1580 (36.1) 1225 (44.7) 2805 (39.4)
Too busy 1214 (27.8) 718 (26.2) 1932 (27.2)
Not interested 648 (14.8) 444 (16.2) 1092 (15.3)
Do not understand what the research entailsa 11/215 (5.1) 5/91 (5.5) 16/306 (5.2)
Other reason 1021 (23.5) 441 (16.1) 1462 (20.5)
Total N = 100 % 4377 2741 7118
aThis option was only on the decline forms for 1020 patients as part of a sub-study. The 5.2 % is based on 306 decliners having this option on the form
they returned
Table 5 Other reasons for declining
Category of reason Reason Depression
n (%)
CVD risk
n (%)
Both conditions
n (%)
Health need-related Health issues 195 (4.5) 50 (1.8) 245 (3.4)
Satisfied with current support for their health 157 (3.6) 65 (2.4) 222 (3.1)
Dissatisfied with health services 21 (0.5) 16 (0.6) 37 (0.5)
Patients’ lives No space in their lives to participate in a trial 158 (3.6) 85 (3.1) 243 (3.4)
Inconvenient at this time 104 (2.3) 85 (3.1) 189 (2.7)
Research-related Perceive themselves as unsuitable 120 (2.7) 14 (0.5) 134 (1.9)
Participation could cause distress 104 (2.4) 29 (1.1) 133 (1.9)
Issues with the research 68 (1.6) 43 (1.6) 111 (1.6)
Telehealth-related Dislikes the proposed intervention 77 (1.8) 25 (0.9) 102 (1.4)
Practical barriers to participating 47 (1.1) 47 (1.7) 94 (1.3)
Patient has communication difficulties 63 (1.4) 29 (11) 92 (1.3)
Unknown Unknown 9 (0.2) 3 (0.1) 12 (0.2)
Total N = 100 % 4327 2718 7045
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This may be because there was a wider age range of pa-
tients included in the depression trial compared to the
CVD risk trial.
Discussion
Although non-participation in telehealth trials is a wide-
spread problem and may introduce bias, this issue has
only been explored within small-scale studies. Our study
appears to be the largest to date to examine two key is-
sues related to this problem in patients with long-term
conditions: the characteristics of patients who do not
participate in telehealth trials (comparing over 24,000 in-
vited patients) and the main reasons for not participat-
ing (responses from over 7000 patients). In total, 82.9 %
of patients did not accept the study invite, which is com-
parable to other telehealth trials [2, 3]. Patients from de-
prived general practices were less likely to accept the
study invite than those from affluent general practices.
This contrasts with one telehealth trial which found no
difference [2], but it is similar to findings in other health
research generally [15, 16]. In the CVD risk trial, youn-
ger patients and BME patients were less likely to accept
the study invite. However, the differences were small.
Overall, reasons for declining could be grouped into
those that were specific to the telehealth intervention,
those that were health need-related, issues related to pa-
tients’ lives and research-related reasons. Firstly, a large
proportion of patients cited issues specific to telehealth
interventions. They did not have access to a computer
or the internet, or sufficient skill to use them; this has
been found elsewhere [2, 4, 18]. The proportion of
patients in this study declining because of technology
reasons was high compared with a recent survey on tele-
health, which reported that 68.5 % had computer tech-
nology available [9]. Our study and this latter survey
were both undertaken as part of the Healthlines Study,
and both included patients with depression and raised
CVD risk. It may be that people in our study gave this
answer as an easy option to decline or that they felt they
needed more access to, or confidence with, technology
in order to engage in these telehealth trials. It is also
surprisingly high because in the patient information
booklets for the Healthlines trials, it was explained to
potential participants that methods were in place to
facilitate access. For example, researchers could help
patients to set up email accounts, and patients were
allowed to use a family member or friend’s email address
or computer.
Older patients were more likely to decline because of
technology reasons, and this is consistent with previous
research [11]. For example, internet availability rates
have been reported as only 26.5 % amongst patients over
74 years old [9]. Consequently, telehealth may be more
accessible for health conditions where patients are
generally younger, for example, cystic fibrosis. Patients
registered at general practices categorised as deprived
were more likely to decline because of technology
reasons, as found in research regarding the uptake of
telehealth in general [14].
Secondly, a common reason for declining was patients
not feeling a need for additional support with their
health, reflecting previous literature [3]. Health problems
could also create a barrier, reflecting an obstacle to par-
ticipation in trials in general [2, 19]. However, this result
does contrast with other studies about the acceptability
of telehealth, which found that poor health was not
related to less interest in telehealth [9]. Consequently, it
may be that declining the trial due to health issues is
related to participation in the trial rather than receiving
the intervention.
Finally, there were a number of reasons offered that
were generic to trials, not just telehealth trials [4, 18, 21,
25, 26]. Some were related to patients’ lives, such as
being too busy. We identified an issue from the free text
answers around emotional capacity to participate in
terms of not having ‘space in their life’, for example,
having caring responsibilities. A proportion of patients
declined for geographical reasons, for example, because
they were moving house or they were frequently away
from home (for example, having a second home abroad).
Table 6 The characteristics of patients declining due to technology issues
Depression CVD risk
Characteristic Categories Technology issues
N (%)
Non-technology issues
N (%)
Total
N =100 %
Technology issues
N (%)
Non-technology issues
N (%)
Total
N =100 %
Gender Female 1493 (49) 1550 (51) 3043 601 (66) 304 (34) 905
Male 667 (50) 663 (50) 1330 1128 (61) 709 (39) 1837
Ethnicity White 2054 (49) 2101 (51) 4155 1615 (63) 938 (37) 2553
BME 43 (52) 39 (48) 82 54 (69) 24 (31) 78
Deprivation Deprived 625 (56) 483 (44) 1108 617 (69) 275 (31) 892
Affluent 1510 (47) 1722 (53) 3232 1112 (60) 738 (40) 1,850
Age (Mean (SD)) 67.4 (13.5) 52.3 (14.53) 67.6 (5.03) 66.9 (5.55)
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These are interesting both in the context of trials and
routine practice of telehealth because they challenge a
key principle of telehealth, which is that it is suitable for
patients who have difficulty attending a general practice
in person [27]. There were also some reasons given that
were research-related, such as not being interested in
participating. It was unclear whether this affected
patients’ desire to participate in the trial or to receive
the telehealth intervention. A small number of patients
declined because they had issues with the research pro-
cedures, such as not wanting to be randomised, confi-
dentiality concerns or regarding the study as a waste of
money. These reasons are consistent with previous lit-
erature [25] and need to be better addressed in patient
information booklets. However, such reasons were only
a small proportion of the reasons that patients declined.
Strengths and limitations
The key strength of the study is that it explored who
does not participate in telehealth trials and the reasons
why. It appears to be by far the biggest study exploring
non-participation in telehealth trials, as the largest study
we have identified included only 625 decliners. It also
explores acceptability of telehealth trials in relation to
two diverse long-term conditions, which is important as
telehealth is often aimed at supporting patients with
their long-term conditions [28].
There were some limitations. First, decline forms were
only returned from 35.6 % of patients who did not
accept the study invite. We do not know why patients
did not respond. We have shown that active decliners
were different from those who simply did not respond.
These demographic differences may have an impact on
the prevalence of the various reasons given for declining.
For example, older people were more likely to return de-
cline forms, but also to cite technology issues as the rea-
son for declining. Therefore, technology reasons may be
less of an issue in the wider patient population than in
our sample. Second, we know little about the impact of
ethnicity. The ethnicity of non-responders was not
known in our study and there were only a small number
of patients from BME groups in the decline population.
Third, it was sometimes unclear whether patients were
declining the trial or the telehealth intervention. Fourth,
over 90 % of responders selected at least one of the pre-
specified reasons for declining. This may be because they
identified the key reasons why patients choose not to
participate in a telehealth trial. However, there is the risk
that patients may have selected those reasons because
they were easy to tick. It is recommended that some of
the other key reasons cited, such as health issues, be
included in future decline forms. Fifth, the sample size
was large and sometimes statistically significant differ-
ences were very small differences and therefore unlikely
to be important. Sixth, this analysis is based on partici-
pation in two trials and the findings may be specific to
the health conditions and the selection criteria for
inviting people.
Implications for telehealth trials and routine practice
The main implication of this research for telehealth tri-
als is that a large proportion of patients with long-term
conditions, especially those in more deprived geograph-
ical areas, either do not have access to the internet or do
not perceive themselves to have the necessary techno-
logical skills required for computer-based telehealth
interventions. Telehealth interventions may be accept-
able to more people if access is facilitated as part of any
intervention, particularly for patients in areas of socio-
economic deprivation. The implication for routine health
care provision is that at present telehealth should not be
the only care option because there is a significant pro-
portion of the population without sufficient technology
skills or access to use it. For example, patients with de-
pression would need to be offered cognitive behavioural
therapy in forms other than computer-based ones (such
as books) or offered considerable technological support.
Another important implication relates to the context-
ual issues of patients’ lives, with patients choosing not to
participate because of health or domestic issues. Given
this, triallists could aim to minimise the commitment
and burden to participants of both the intervention and
the trial. Additionally, there were some differences in the
reasons for declining between the depression and CVD
risk trials, which indicates that whilst there are similar-
ities in telehealth trials, the specific reasons may differ
depending on the population from which the trial is
recruiting. It is recommended that future telehealth
trials include a similar process of exploring why patients
decline to participate to help build a picture of issues
affecting participation for different health conditions.
Finally, a key reason for concern about low participa-
tion rates in trials is that this may lead to recruitment
bias, with those patients included in the trial not being
representative of those for whom the intervention would
be provided in routine clinical practice. This was not the
most pressing issue here. Most patients declining did so
because they felt that telehealth was not suitable for
them rather than for reasons related to the research.
Conclusions
In both trials, patients from deprived general practices
were more likely to decline the study invite. Patients
provided a range of reasons for declining to participate
in a telehealth trial, and these reasons were generally
consistent with the literature from the few other tele-
health trials, as well as from trials more generally. Some
reasons were specific to telehealth, such as not having
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internet access; others were generic to all studies, such
as being too busy. However, some reasons were specific
to individuals’ health needs, and so were different across
the two groups of long-term conditions recruited to this
study. The primary reason for declining was due to tech-
nology issues; this was the case for patients who were
registered at general practices in deprived areas. This
has implications for the feasibility of both telehealth tri-
als and telehealth in routine practice. For some patients,
it was not clear if they were declining to participate in
the trial or the intervention per se, for example, patients
who said that they were not interested. If the latter, it
raises questions about the acceptability of the telehealth
intervention. It is recommended that other trials also
explore why patients are not participating to facilitate a
greater understanding of non-participation.
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